Friday, February 24, 2017 4:20:46 PM
One other thing I observed, probably completely unrelated, was
CTO (confidential treatment order) filed with SEC for ARGS (Argos Therapeutics) in mid December 2016. Still not explained to my knowledge.
Two board members voluntarily resigned at ARGS on December 9, 2017. Both happened to be on the compensation committee. No apparent reason for resignation.
CEO Jeff Abbey signed 40 thousand square foot lease in North Carolina mid January 2017, one month after the board resignations and CTO (confidential treatment order) and one month before trial failure.
On January 23, 2017, the company no longer marked that it was in an FDA regulated trial in clinicaltrials.gov.
On February 6, 2017, the company CEO Jeff Abbey gave an interview to Seeking Alpha blogger just before AGS-003 failed in its phase III trial, and admitted that the last patient was enrolled in mid October 2015 (ARGOS ARGS had initially PR'd in mid July 2015 that they completed enrollment.) A lot of small Board stock purchases in October 2016.
Oh, and on February 6, 2017, the partial hold on the NWBO's phase iii DCVax-L trial was lifted.
On February 22, 2017, ARGS announced the phase III trial failed due to futility without providing any statistical and/or data details.
Also on February 22, 2017, AGEN "quietly" announced its phase III GBM trial failure.
I have no idea what all that means. Perhaps just lots of coincidences, typos and such.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM